JP2003518507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003518507A5 JP2003518507A5 JP2001548135A JP2001548135A JP2003518507A5 JP 2003518507 A5 JP2003518507 A5 JP 2003518507A5 JP 2001548135 A JP2001548135 A JP 2001548135A JP 2001548135 A JP2001548135 A JP 2001548135A JP 2003518507 A5 JP2003518507 A5 JP 2003518507A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- inducer
- inhibitor
- description
- obstruction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 description 20
- 239000000411 inducer Substances 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 2
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 2
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 1
- 108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- -1 Or claim 18molecule Substances 0.000 description 1
- 102000004393 TNF receptor-associated factor 2 Human genes 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 102000003718 TNF receptor-associated factor 5 Human genes 0.000 description 1
- 108090000001 TNF receptor-associated factor 5 Proteins 0.000 description 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9930616.9 | 1999-12-24 | ||
| GBGB9930616.9A GB9930616D0 (en) | 1999-12-24 | 1999-12-24 | Activation and inhibition of the immune system |
| PCT/GB2000/004925 WO2001047543A2 (en) | 1999-12-24 | 2000-12-22 | Activation and inhibition of the immune system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003518507A JP2003518507A (ja) | 2003-06-10 |
| JP2003518507A5 true JP2003518507A5 (enExample) | 2008-02-28 |
Family
ID=10867023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001548135A Pending JP2003518507A (ja) | 1999-12-24 | 2000-12-22 | 免疫系の活性化および阻害 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7915009B2 (enExample) |
| EP (2) | EP1244466B1 (enExample) |
| JP (1) | JP2003518507A (enExample) |
| CN (2) | CN100563707C (enExample) |
| AT (1) | ATE390929T1 (enExample) |
| AU (1) | AU781496B2 (enExample) |
| CA (1) | CA2394880A1 (enExample) |
| DE (1) | DE60038503T2 (enExample) |
| ES (1) | ES2302707T3 (enExample) |
| GB (1) | GB9930616D0 (enExample) |
| NZ (1) | NZ519438A (enExample) |
| WO (1) | WO2001047543A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9930616D0 (en) | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| JP2004522432A (ja) * | 2000-12-22 | 2004-07-29 | シノヴィス・リミテッド | Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法 |
| GB0116249D0 (en) * | 2001-07-05 | 2001-08-29 | Imp College Innovations Ltd | Methods |
| JP2003055202A (ja) * | 2001-08-15 | 2003-02-26 | Hiroyuki Hanai | 炎症性腸疾患の予防・治療剤 |
| EP1512415A4 (en) * | 2002-05-29 | 2005-11-09 | Anges Mg Inc | LURE COMPOSITION FOR TREATING AND PREVENTING INFLAMMATORY DISEASES |
| AU2002953094A0 (en) * | 2002-12-04 | 2002-12-19 | The University Of Queensland | Immunomodulating compositions, processes for their production and uses therefor |
| WO2004027063A1 (en) * | 2002-09-19 | 2004-04-01 | Institut National De La Sante Et De La Recherche Medicale-Inserm | Use of sirnas for gene silencing in antigen presenting cells |
| EP2557164A1 (en) * | 2003-02-18 | 2013-02-13 | Kevin M. Slawin | Induced activation in dendritic cells |
| JP2007515937A (ja) * | 2003-05-08 | 2007-06-21 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | ＮＦ−κＢの調節機構 |
| TWI487535B (zh) | 2004-11-30 | 2015-06-11 | Centocor Inc | 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途 |
| CN100418532C (zh) * | 2005-06-17 | 2008-09-17 | 吕志民 | 治疗多种疾病的NF-κB化合物抑制剂 |
| CA2613166A1 (en) * | 2005-06-23 | 2007-01-04 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
| US20080311552A1 (en) * | 2005-09-20 | 2008-12-18 | London Health Sciences Centre Research, Inc. | Use of Sirnas in Organ Storage/Reperfusion Solutions |
| DK1945820T3 (da) | 2005-10-27 | 2013-11-11 | Janssen Biotech Inc | Toll-lignende receptor-3-modulatorer, fremgangsmåder og anvendelser |
| CN101240271B (zh) * | 2006-08-28 | 2012-08-29 | 长春华普生物技术有限公司 | Toll样受体调节性寡核苷酸及其用途 |
| AU2007306936B2 (en) | 2006-10-12 | 2014-02-06 | The University Of Queensland | Compositions and methods for modulating immune responses |
| EP2076272B1 (en) * | 2006-10-19 | 2015-07-29 | Baylor College Of Medicine | Generating an immune response by inducing cd40 and pattern recognition receptors |
| WO2008080195A1 (en) * | 2006-12-29 | 2008-07-10 | The University Of Queensland | Compositions and methods for treating or preventing unwanted immune responses |
| DK2331680T3 (en) * | 2008-09-22 | 2017-08-21 | Baylor College Medicine | Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| PT3366302T (pt) * | 2011-07-18 | 2022-03-07 | Univ Kentucky Res Found | Proteção de células da degeneração induzida por rna alu e inibidores para proteger as células |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| KR20150131218A (ko) | 2013-03-14 | 2015-11-24 | 벨리쿰 파마슈티컬스, 인크. | T 세포 증식의 제어 방법 |
| CA2912172A1 (en) | 2013-06-05 | 2014-12-11 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| ES2761280T3 (es) * | 2013-09-12 | 2020-05-19 | Icahn School Med Mount Sinai | Métodos de producción de animales transgénicos con receptores de células T que son específicos de una proteína fluorescente |
| CN106132423B (zh) | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| WO2015187847A1 (en) * | 2014-06-03 | 2015-12-10 | Cure-It Lifesciences, Llc | Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml) |
| JP6868554B2 (ja) | 2014-09-02 | 2021-05-12 | ベリカム ファーマシューティカルズ， インコーポレイテッド | ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激 |
| AU2015341481C1 (en) | 2014-11-03 | 2021-09-16 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T cell receptors directed against Bob1 and uses thereof |
| AU2015360502A1 (en) | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| US10420836B2 (en) | 2015-10-08 | 2019-09-24 | Emory University | Methods of immunizing a subject and compositions related thereto |
| MX2021014679A (es) | 2019-05-31 | 2022-04-06 | Janssen Pharmaceutica Nv | Inhibidores de molécula pequeña de quinasa inductora de nf-kb. |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US5149796A (en) | 1989-08-31 | 1992-09-22 | City Of Hope | Chimeric DNA-RNA catalytic sequences |
| AU650249B2 (en) | 1989-11-03 | 1994-06-16 | Immulogic Pharmaceutical Corporation | A human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor |
| US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| JP3418982B2 (ja) | 1990-10-31 | 2003-06-23 | ソマティクス セラピー コーポレイション | 内皮細胞の遺伝的変性 |
| WO1994024281A1 (en) | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| CA2105595A1 (en) * | 1992-09-23 | 1994-03-24 | Ramaswamy Narayanan | Antisense polynucleotides |
| US5951988A (en) | 1993-03-30 | 1999-09-14 | University Of Saskatchewan | Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
| US5405941A (en) * | 1993-04-15 | 1995-04-11 | National Jewish Center For Immunology And Respiratory Medicine | MEKK protein, capable of phosphorylating MEK |
| ATE204300T1 (de) | 1994-05-13 | 2001-09-15 | Biovation Ltd | Zielzellen-bindende chimäre peptide |
| CA2195642A1 (en) | 1994-07-27 | 1996-02-08 | Andreas Suhrbier | Polyepitope vaccines |
| US5597898A (en) * | 1995-02-15 | 1997-01-28 | Yale University | NF-κB activation regulatory protein, IκB-β |
| AU6181196A (en) | 1995-06-29 | 1997-01-30 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal mast cell stabilizers |
| EP0779361A3 (en) * | 1995-12-15 | 1999-11-10 | F. Hoffmann-La Roche Ag | Truncated form of inhibitory kappa B protein (1kB), recombinant production and uses thereof |
| UA71889C2 (uk) * | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
| US6294378B1 (en) | 1996-07-26 | 2001-09-25 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| AU729247B2 (en) * | 1996-08-12 | 2001-01-25 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
| JP4695735B2 (ja) * | 1996-08-26 | 2011-06-08 | シグナル ファーマシューティカルズ， エルエルシー | 刺激誘導性Ｉ（κ）Ｂキナーゼ［ＩＫＫ］シグナルソーム |
| US5891924A (en) * | 1996-09-26 | 1999-04-06 | Research Development Foundation | Curcumin (diferuloylmethane) inhibition of NFκB activation |
| WO1998028424A2 (en) * | 1996-12-23 | 1998-07-02 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
| US6924308B1 (en) * | 1997-07-30 | 2005-08-02 | Howard L. Elford | Therapeutic process for inhibiting NF-κB |
| US5952483A (en) * | 1997-07-31 | 1999-09-14 | Smithkline Beecham Corporation | Human IκB-β |
| EP0897009A3 (en) * | 1997-08-04 | 1999-06-09 | Smithkline Beecham Plc | HKABY60 polypeptides |
| JPH1171278A (ja) * | 1997-09-01 | 1999-03-16 | Kanegafuchi Chem Ind Co Ltd | 転写因子ＮＦ−κＢ活性化阻害剤 |
| GB9719238D0 (en) | 1997-09-11 | 1997-11-12 | Mathilda & Terence Kennedy Ins | Viral infection of cells |
| US6503184B1 (en) * | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US5965421A (en) * | 1997-11-26 | 1999-10-12 | Human Genome Sciences, Inc. | Human IRAK-2 |
| EP1119618A2 (en) * | 1998-02-19 | 2001-08-01 | Peter Bromley | Stress promoter control of therapeutic genes in gene therapy: compositions and methods |
| JP2002513552A (ja) * | 1998-05-06 | 2002-05-14 | フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー | ＮＦ−κＢ活性化の新規な阻害剤 |
| HUP0102782A3 (en) * | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
| GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| CA2367692A1 (en) * | 1999-03-15 | 2000-09-21 | Introgen Therapeutics, Inc. | Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses |
| GB9930616D0 (en) | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| JP2004522432A (ja) | 2000-12-22 | 2004-07-29 | シノヴィス・リミテッド | Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法 |
| GB0116249D0 (en) | 2001-07-05 | 2001-08-29 | Imp College Innovations Ltd | Methods |
-
1999
- 1999-12-24 GB GBGB9930616.9A patent/GB9930616D0/en not_active Ceased
-
2000
- 2000-12-22 AT AT00985660T patent/ATE390929T1/de not_active IP Right Cessation
- 2000-12-22 ES ES00985660T patent/ES2302707T3/es not_active Expired - Lifetime
- 2000-12-22 EP EP00985660A patent/EP1244466B1/en not_active Expired - Lifetime
- 2000-12-22 DE DE60038503T patent/DE60038503T2/de not_active Expired - Lifetime
- 2000-12-22 JP JP2001548135A patent/JP2003518507A/ja active Pending
- 2000-12-22 NZ NZ519438A patent/NZ519438A/en not_active IP Right Cessation
- 2000-12-22 AU AU22062/01A patent/AU781496B2/en not_active Ceased
- 2000-12-22 WO PCT/GB2000/004925 patent/WO2001047543A2/en not_active Ceased
- 2000-12-22 US US10/168,805 patent/US7915009B2/en not_active Expired - Fee Related
- 2000-12-22 CN CNB200610051522XA patent/CN100563707C/zh not_active Expired - Fee Related
- 2000-12-22 CN CNB008191050A patent/CN1254272C/zh not_active Expired - Fee Related
- 2000-12-22 CA CA002394880A patent/CA2394880A1/en not_active Abandoned
- 2000-12-22 EP EP07014428A patent/EP1852123A3/en not_active Withdrawn
-
2007
- 2007-12-06 US US11/987,956 patent/US20080124322A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003518507A5 (enExample) | ||
| Maloy et al. | Intralymphatic immunization enhances DNA vaccination | |
| KR100615109B1 (ko) | 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원 | |
| CN103998056B (zh) | 用于接种抗金黄色葡萄球菌疫苗的方法和组合物 | |
| JP2018509935A5 (enExample) | ||
| JP2007528217A (ja) | スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド | |
| Cong et al. | Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice | |
| JP5745577B2 (ja) | Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 | |
| Tan et al. | Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen | |
| CN1610697A (zh) | 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途 | |
| Senti et al. | Intralymphatic immunotherapy: from the rationale to human applications | |
| Birnbaum et al. | Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): I. Immunization with a peptide of the myelin protein 2′, 3′ cyclic nucleotide 3′ phosphodiesterase that is cross‐reactive with a heat shock protein alters the course of EAE | |
| CN106163540A (zh) | 用于治疗蛋白病或构象病的聚集蛋白和分子伴侣的组合 | |
| JP2015529677A5 (enExample) | ||
| CN1316431A (zh) | 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用 | |
| CN100467063C (zh) | 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用 | |
| JP2010535504A5 (enExample) | ||
| JP2008500043A (ja) | 黄色ブドウ球菌に対する感染防御免疫応答を誘導するためのポリペプチド | |
| JP2005512518A5 (enExample) | ||
| Guo et al. | Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma | |
| Rego et al. | Monophosphoryl lipid-A: a promising tool for Alzheimer’s disease toll | |
| JP2006523185A5 (enExample) | ||
| AU2013339846B2 (en) | Chimeric vaccine antigens against hepatitis C virus | |
| JP2009511452A5 (enExample) | ||
| MX2008016059A (es) | Composiciones farmaceuticas que contienen un anticuerpo monoclonal anti-idiotipico anti-ca-125 y derivados de aluminio. |